Focus on ulcerative colitis: stable gastric pentadecapeptide BPC 157.
Sikiric. P P; Seiwerth. S S; Rucman. R R; Turkovic. B B; Rokotov. D S DS; Brcic. L L; Sever. M M; Klicek. R R; Radic. B B; Drmic. D D; Ilic. S S; Kolenc. D D; Stambolija. V V; Zoricic. Z Z; Vrcic. H H; Sebecic. B B
Key Findings
- Stable in gastric juice and active throughout the GI tract.
- Demonstrated anti‑ulcer and wound‑healing benefits in animal models of intestinal surgery, short‑bowel syndrome, and fistulas.
- Interacts with the nitric‑oxide system to protect endothelium and promote angiogenesis, while up‑regulating genes involved in collagen and growth‑factor production.
- Phase II human trial in ulcerative colitis showed efficacy with a clean safety profile (no toxic effects, no LD50 reached).
Practical Outcomes
- For biohackers focused on gut health, BPC‑157 looks like a promising candidate for supporting ulcer healing and intestinal repair, especially in conditions like ulcerative colitis or after gut surgery. While it isn’t FDA‑approved, the peptide can be sourced from reputable peptide vendors; typical experimental doses range from 200–500 µg injected subcutaneously once or twice daily. Users should start with the lowest effective dose, monitor for any adverse reactions, and understand that clinical evidence is still limited to early‑phase studies.
Summary
BPC‑157 is a tiny protein that survives stomach acid and has shown strong ulcer‑healing and gut‑repair effects in animal studies and early human trials for inflammatory bowel disease. It appears safe, with no reported toxicity, and may boost blood‑vessel health and collagen production, which are key for fixing damaged intestines.
Abstract
Stable gastric pentadecapeptide BPC 157 (GEPPPGKPADDAGLV, M.W. 1419) may be the new drug stable in human gastric juice, effective both in the upper and lower GI tract, and free of side effects. BPC 157, in addition to an antiulcer effect efficient in therapy of inflammatory bowel disease (IBD) (PL 14736) so far only tested in clinical phase II, has a very safe profile, and exhibited a particular wound healing effect. It also has shown to interact with the NO-system, providing endothelium protection and angiogenic effect, even in severely impaired conditions (i.e., it stimulated expression of early growth response 1 gene responsible for cytokine and growth factor generation and early extracellular matrix (collagen) formation (but also its repressor nerve growth factor 1-A binding protein-2)), important to counteract severe complications of advanced and poorly controlled IBD. Hopefully, the lessons from animal studies, particularly advanced intestinal anastomosis healing, reversed short bowel syndrome and fistula healing indicate BPC 157's high significance in further IBD therapy. Also, this supportive evidence (i.e., no toxic effect, limit test negative, LD1 not achieved, no side effect in trials) may counteract the problems commonly exercised in the use of peptidergic agents, particularly those used on a long-term basis.
Study Information
pubmed
2012
10.2174/092986712803414015
56
68